This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The model was not described in detail, and no diagram was supplied. The focus of the study was on the economic impact of the quadrivalent vaccine, so the authors reported only limited details of the health outcomes. It would have been useful if these outcomes were reported in a table for each of the influenza seasons, as for the costs. For the probabilistic sensitivity analysis, the authors stated that the initial values were varied over given ranges, but these ranges were not justified, and the distributions used were not reported. Only a selection of parameters was varied and uncertainty in effectiveness data was not explored. Confidence intervals for each of the cost outcomes were reported, but no diagrams for the probabilistic sensitivity analysis results were reported, and the impact of uncertainty was not discussed in the text.
Concluding remarks:
The reporting was limited, in some areas, making it hard to assess the appropriateness of the authors' conclusions.
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